CAR T-cell Therapy Market is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% | Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company.

The Global CAR-T cell therapy market reached US$ 4.8 billion in 2024 and is expected to reach US$ 20.4 billion by 2033, growing at a CAGR of 16.3% during the forecast period 2025-2033.

CAR T-cell Therapy Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research methods, it offers comprehensive reports that help clients navigate complex market landscapes, drive strategic growth, and seize new opportunities in an ever-evolving global market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/car-t-cell-therapy-market?rk

CAR T-cell therapy is an advanced immunotherapy in which a patient's T-cells are genetically modified to recognize and attack cancer cells. The engineered T-cells express a chimeric antigen receptor (CAR) that targets specific tumor antigens. This therapy has shown remarkable success in treating blood cancers such as leukemia and lymphoma. While highly effective, CAR T-cell therapy can cause severe immune reactions, such as cytokine release syndrome. Researchers are working to expand its applications to solid tumors and enhance its safety profile.

List of the Key Players in the CAR T-cell Therapy Market:

Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company, Johnson & Johnson, Autolus Therapeutics, Pfizer Inc., BioNTech SE., Merck KGaA, Allogene Therapeutics, Atara Biotherapeutics, Inc.

Emerging Players
The emerging players in the CAR-T cell therapy market include AstraZeneca, Eli Lilly and Company, JW Therapeutics, and among others.

Industry Development:

In March 2024, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undergone at least two prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. Continued approval for this indication depends on the verification and demonstration of clinical benefit in confirmatory trials.

Growth Forecast Projected:

The Global CAR T-cell Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2033. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global CAR T-cell Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/car-t-cell-therapy-market?rk

Segment Covered in the CAR T-cell Therapy Market:

By Therapy Type: Autologous CAR-T Cell Therapy, Allogeneic CAR-T Cell Therapy.

By Drug Type: Abecma, Breyanzi, Carvykti, Tecartus, Kymriah, Yescarta.

By Target Antigen: BCMA (B-cell maturation antigen), CD20, CD22, CD30, CD33, GD2, HER2, Others.

By Application: Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma, Others.

Regional Analysis for CAR T-cell Therapy Market:

The regional analysis of the CAR T-cell Therapy Market covers key regions including North America, Europe, Asia Pacific Middle East and Africa and South America. The North America with a focus on the U.S., Canada, and Mexico; Europe, highlighting major countries like the U.K., Germany, France, and Italy, along with other nations in the region; Asia-Pacific, covering India, China, Japan, South Korea, and Australia, among others; South America, with emphasis on Colombia, Brazil, and Argentina; and the Middle East & Africa, which includes Saudi Arabia, the U.A.E., South Africa, and other countries. This comprehensive regional breakdown helps identify unique market trends and growth opportunities specific to each area.

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

âž¡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.

âž¡ Top-down and bottom-up approach for regional analysis

âž¡ Porter's five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players.

âž¡ By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Market

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/car-t-cell-therapy-market?rk

People Also Ask:

âž  What is the global sales, production, consumption, import, and export value of the CAR T-cell Therapy market?

âž  Who are the leading manufacturers in the global CAR T-cell Therapy industry? What is their operational status in terms of capacity, production, sales, pricing, costs, gross margin, and revenue?

âž  What opportunities and challenges do vendors in the global CAR T-cell Therapy industry face?

âž  Which applications, end-users, or product types are expected to see growth? What is the market share for each type and application?

âž  What are the key factors and limitations affecting the growth of the CAR T-cell Therapy market?

âž  What are the various sales, marketing, and distribution channels in the global industry?

Browse More Reports: https://www.datamintelligence.com/research-report/car-t-cell-therapy-market?rk

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.